Servicios Personalizados
Revista
Articulo
Indicadores
- Citado por SciELO
- Accesos
Links relacionados
- Similares en SciELO
Compartir
Medicina interna de México
versión impresa ISSN 0186-4866
Resumen
SOLACHE-ORTIZ, G. et al. Role of spironolactone in the treatment of resistant hypertension. Med. interna Méx. [online]. 2017, vol.33, n.6, pp.797-808. ISSN 0186-4866. https://doi.org/10.24245/mim.v33i6.1452.
This article provides useful tools for the diagnosis and differential diagnosis of resistant hypertension. Here, we refer the recommendations of the main international guidelines of management respect to the target goals of the blood pressure, the failure of triple therapy in a large percentage of patients and the factors for the rational choice of the fourth agent for the institution of a quadruple therapy. This choice is based on the ability of spironolactone, antagonist of aldosterone receptors, to inhibit the deleterious effects of aldosterone that difficult the control of blood pressure and increase the cardiovascular risk in a high percentage of patients.
Palabras llave : aldosterone; aldosterone antagonists; spironolactone; resistant hypertension; ambulatory 24-hour blood pressure monitoring.